

# Test Catalog

Diagnostic. Prognostic. Predictive. Predisposition.





## NUP98

#### **Alternative Name**

Nucleoporin 98

## Methodology

**FISH** 

## **Test Description**

Disease(s): Acute Myeloid Leukemia

**Probes:** NUP98 (11p15.4)

## Clinical Significance

Fusions of the nucleoporin 98 (NUP98) gene with more than 30 partner genes are noted in a variety of hematologic malignancies including AML, MDS, and T-ALL. Recurring NUP98 fusions, such as NUP98-NSD1, NUP98-JARID1A, and NUP98-HOXA9, have been reported in pediatric and adult cytogenetically normal AML (CN-AML) and some have been associated with poor prognosis. Detection of NUP98 rearrangement may be useful to further classify prognostic risk in AML and guide therapy selection. Screening for NUP98 rearrangement in pediatric AML patients at the time of diagnosis has been suggested. This NUP98 break-apart FISH test is designed to detect NUP98 rearrangements with potentially any known or novel translocation partner.

## **Specimen Requirements**

- Bone Marrow Aspirate: 1-2 mL sodium heparin tube. EDTA tube is acceptable.
- Peripheral Blood: 2-5 mL sodium heparin tube. EDTA tube is acceptable.
- Fresh, Unfixed Tissue: Tissue in RPMI.
- Fluids: Equal parts RPMI to specimen volume.
- Paraffin Block or Cut Slides: Not available.
- **Note:** Please exclude biopsy needles, blades, and other foreign objects from transport tubes. These can compromise specimen viability and yield, and create hazards for employees.

#### **Storage & Transportation**

Refrigerate specimen. Do not freeze. Use cold pack for transport, making sure cold pack is not in direct contact with specimen. For fresh samples: ship same day as drawn whenever possible; specimens <72 hours old preferred.

## CPT Code(s)\*

88377x1 manual or 88374x1 automated

#### **New York Approved**

Yes

#### **Level of Service**

Technical, Global

#### **Turnaround Time**

3-5 days

#### References

- 1. Ostronoff F, Othus M, Gerbing RB, et al. NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report. *Blood*. 2014;124(15):2400-2407.
- 2. Hollink I, van den Heuvel-Eibrink M, Arentsen-Peters S, et al. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. *Blood.* 2017;118(13):3645-3656.
- 3. Romana SP, Radford-Weiss I, Ben Abdelali R, et al. NUP98 rearrangements in hematopoietic malignancies: a study of the Groupe Francophone de Cytogenetique Hematologique. *Leukemia*. 2006;20:696-706.

Please direct any questions regarding coding to the payor being billed.

<sup>\*</sup>The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing partnership opportunities, and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing, FISH, cytogenetics, flow cytometry, and immunohistochemistry through our nation-wide network of CAP-accredited, CLIA-certified laboratories.

Committed to research as the means to improve patient care, we provide Pharma Services for pharmaceutical companies, in vitro diagnostic manufacturers, and academic scientist-clinicians. We promote joint publications with our client physicians. NeoGenomics welcomes your inquiries for collaborations. Please contact us for more information.

\*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.



9490 NeoGenomics Way Fort Myers, FL 33912

Phone: 239.768.0600/ Fax: 239.690.4237

neogenomics.com

© 2024 NeoGenomics Laboratories, Inc. All Rights Reserved. All other trademarks are the property of their respective owners

Rev. 051324